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Abstract
Background: Aluminium is considered a bone toxic metal since poisoning can lead to aluminium-
induced bone disease in patients with chronic renal failure. Healthy subjects with normal renal
function retain 4% of the aluminium consumed. They might thus also accumulate aluminium and
eventually be at risk of long-term low-grade aluminium intoxication that can affect bone health.
Methods: We therefore examined 62 patients with femoral neck fractures or osteoarthritis of the
hip (age range 38–93), with the aim of examining whether aluminium in bone is associated with
bone-mineral density (BMD), content (BMC) or width of the femoral neck measured by dual-
energy X-ray absorptiometry (DXA). During operations bone biopsies were taken from the
trabecular bone of the proximal femur. The samples were measured for their content of aluminium
using a mass spectrometer.
Results: No significant association between the aluminium content in bone and femoral neck BMD,
BMC or width could be found after multivariate adjustment.
Conclusion: Our results indicate that the accumulated aluminium content in bone during life does
not substantially influence the extent of osteoporosis.
Background
Osteoporosis is a common disease in the elderly, and is
characterised by a generalised reduction in bone-mineral
density (BMD) or mass (BMC), microarchitectural deteri-
oration of bone tissue and an increased risk of low-energy
fractures. The disease is divided in two groups: primary
and secondary osteoporosis. Primary osteoporosis is
becoming more prevalent with ageing and is influenced
by many different environmental factors and lifestyles, as
well as genetic disposition [1-9]. Aluminium, one poten-
tial environmental factor of interest for bone disease, is
the third most common element in the earth's crust and
the most abundant metal (8%), and is widely utilised in
industry. Owing to its low solubility and because of its
deposition as sediment in the form of aluminium hydrox-
ide, only small amounts of aluminium in solution are
usually found in water (< 10 μg/l). However, aluminium
levels are higher in an acidified environment due to acid
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rain or in water treated with aluminium sulphate, i.e. in
waterworks for the chemical removal of particles in drink-
ing water. Aluminium is also naturally present in many
foods, and total dietary intake has been estimated at 4–9
mg Al/day [10-14]. While aluminium normally enters the
body through the diet, intoxication by inhalation of alu-
minium-containing gas is a rare, but occasionally occurs
in the aluminium-processing industries. On average, 4%
of the aluminium content of the diet is retained by intes-
tinal absorption, and might partially be accumulated in
bone, the main storage site of aluminium [15,16]. In the
elderly and in patients with Alzheimer-type pathology,
the intestinal absorption of aluminium is increased
[17,18], thus augmenting the amount of aluminium
stored in bone. In the bloodstream, most aluminium is
eliminated through the kidneys.
Given its wide use and occurrence, the conceivable harm-
ful potential of aluminium for negative biological conse-
quences in humans is high. It is well known in patients
with chronic renal failure that aluminium poisoning may
lead to three types of disorder: aluminium-induced bone
disease (AIBD), microcytic anaemia and encephalopathy
[19-22,17,23-27,18,28], but since healthy subjects with
normal renal function also retain aluminium, they poten-
tially risk long-term accumulation and low-grade alumin-
ium intoxication [15,29-31]. Furthermore, osteomalacia-
like bone disease has been reported in patients who
required long-term total parenteral nutrition (TPN) [32-
34] owing to the aluminium contamination of the protein
source used.
The aim of this study was to examine whether the alumin-
ium concentration in bone is associated with BMD, BMC
or size of the proximal femur in middle-aged and elderly
men and women.
Methods
In total, 62 patients – 41 women and 21 men – with a
mean age of 72, range 38–93, were included in this study,
and all characteristics are shown in Table 1. They were
treated at either of the two hospitals in the county of Upp-
sala. They were admitted to hospital for arthroplasty
because of osteoarthritis of the hip (ICD X code M161, n
= 34, mean age 63 years; range 38–90 years) or for hip
fracture (ICD X codes S720 or S721, n = 28, mean age 82
years; range 72–93 years). Of these hip-fractures cases, 13
had a diagnosis of dementia on admission to hospital,
while 15 patients had no reported mental illness. None of
the patients operated on for osteoarthritis were recognised
as being demented.
Creatinine in serum was measured kinetically as a creati-
nine-picrate complex based on a modified Jaffe's reaction
in a spectrophotometer. The coefficient of variation (CV)
was 2.1% and the normal reference interval was set to 60–
106 μmol/l. Creatinine clearance in ml/minute was esti-
mated using the Cockroft and Gault equation [35],
including the variables serum creatinine, body weight,
height, age and sex.
During the operations in all cases, bone biopsies from the
trabecular bone of the proximal femur (i.e. Trochanter
major, after drilling the hole for the osteosynthesis screws
or after preparation for the prosthetic femur stem in cases
of arthroplasty) were taken using an aluminium-free
instrument. The mean weights of the samples were 300
mg (range 29–600 mg). The bone samples were immedi-
ately put in sealed polyethylene test tubes, frozen and
stored at -20°C until analysis. Prior to analysis, after dry-
ing at 120°C for 48 hours, the bone samples were
weighed. Thereafter, the biopsies were decomposed using
ultra-pure nitric acid in a quartz tube, and an internal
standard (Indium) was added, diluted with high-purity
water (with a resistivity of more than 18 MΩ-cm). The
samples were then introduced into an inductively coupled
mass spectrometer (Perkin-Elmer Elan 6000) and meas-
ured for their content of aluminium. All handling of the
samples was in a clean room. Quality control was per-
formed using a reference material (IAEA H-8 Animal
bone) in every fifth sample randomly distributed in the
measurement series. The coefficient of variation (CV) for
the method was 4.7% [36].
Femoral-neck and total hip BMD (g/cm2), BMC (g/cm)
together with neck width (cm) and area (cm2) measure-
ments were performed using dual energy X-ray absorpti-
ometry (DPX-L™, Lunar Co, Madison, Wi, USA) of the
contralateral unfractured/nonoperated proximal femur.
The scans were performed within one week of the fracture
event, or in arthroplasty cases 1–2 days before the opera-
tion. The equipment's precision error expressed as CV was
evaluated using a spine phantom and was less than 1%.
Table 1: Characteristics of the participants (n = 62).
Mean (SD) Range
Age (years) 38 – 93
Aluminium ng/g dw 1262 (1377) 58 – 6435
log Aluminium 2.9 (0.4) 1.8 – 3.8
Weight (kg) 70 (14) 44 – 102
Height (m) 1.67 (0.09) 1.49 – 1.9
BMI (Kg/m2) 24.6 (3.4) 19 – 32
Creatinine (μmol/l) 92 (20) 64 – 187
Creatinine clearance (ml/minute) 50 (19) 19 – 93
BMD femoral neck (g/cm2) 0.81 (0.18) 0.46 – 1.25
BMC femoral neck (g) 4.20 (1.23) 1.96 – 7.25
BMD total hip (g/cm2) 0.86 (0.19) 0.54 – 1.29
BMC total hip (g) 30.3 (8.1) 15.0 – 49.7
Width femoral neck (cm) 5.2 (0.7) 3.0 – 6.6
Area femoral neck (cm2) 34.9 (4.0) 26.6 – 46.4BMC Musculoskeletal Disorders 2006, 7:69 http://www.biomedcentral.com/1471-2474/7/69
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The Ethics Committee of the Medical Faculty of Uppsala
University approved the study.
Statistical analysis
The measured aluminium levels of the bones displayed a
skewed distribution. In all analysis we therefore used alu-
minium values transformed to natural logarithms – val-
ues which in turn were normally distributed (Shapiro-
Wilk test p = 0.45). The crude and the multivariate
adjusted results with sex, age (by 10-year groups), body-
mass index (kg/m2, continuous), height (continuous),
demented hip-fracture cases (dichotomous) and non-
demented hip-fracture cases (dichotomous) by linear
regression modelling are presented. To detect non-linear
associations we used the mean multivariate adjusted BMD
and BMC values by tertiles of aluminium content of the
bones, using the GLM (general linear models) procedure
in the SAS package (version 8, SAS Institute, Cary, NC,
USA).
Results
All samples contained aluminium, ranging from 58 to
6435 ng/g dw. We found an increase in aluminium con-
tent of bone with age (R2 = 0.3, p < 0.0001). The average
aluminium values, adjusted for age, were similar in men
and women (p = 0.47).
Using a crude linear-regression analysis model, we found
a strong association between aluminium and BMD as well
as with BMC, but after multivariate adjustment including
age these associations did not remain significant (Table
2). Furthermore, there were no differences in adjusted
mean BMD or BMC values between tertiles of aluminium
content in bone (Figures 1 and 2). In addition, we could
neither find an association between aluminium in bone
and bone density nor any association regarding mass
within subgroups such as demented or non-demented
participants among those with hip fracture or osteoarthri-
tis patients or in any gender. No associations were found
Tertiles Al-BMD Figure 1
Tertiles Al-BMD. Average adjusted bone-mineral density 
and content values of the femoral neck by tertiles of alumin-
ium content of bone. Included in the multivariate model were 
sex, age (by 10-year groups), body-mass index (continuous), 
height (continuous), creatinine clearance (continuous), 
demented hip fracture cases (dichotomous) and non-
demented hip-fracture cases (dichotomous).
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Table 2: Results of linear-regression analysis using logarithmically transformed aluminium values as independent variables, and bone-
mineral density (BMD) and content (BMC) of the total hip and femoral neck as dependent variables.
Univariate 
model β (SE)
95% 
confidence 
interval of β
p-value Multivariate 
model β (SE)
95% 
confidence 
interval of β
p-value
Unit of exposure
BMD femoral neck (g/cm2) ** -0.098 (0.02) -0.137; -0.059 <0.0001 -0.023 (0.015) -0.054; 0.008 0.14
*** -0.039 (0.008) -0.055; -0.024 <0.0001 -0.010 (0.006) -0.022: 0.003 0.13
BMD total hip (g/cm2) ** -0.088 (0.021) -0.131; -0.045 0.0001 -0.013 (0.015) -0.044; 0.018 0.39
*** -0.035 (0.009) -0.052; -0.018 0.0001 -0.006 (0.007) -0.020; 0.007 0.36
BMC femoral neck (g/cm) ** -0.56 (0.14) -0.84;-0.29 0.0001 -0.09 (0.11) -0.32; 0.13 0.41
*** -0.22 (0.05) -0.33;-0.12 0.0001 -0.04 (0.05) -0.14; 0.05 0.38
BMC total hip (g/cm) ** -3.00 (0.95) -4.91; -1.10 0.003 -0.31 (0.63) -1.56; 0.95 0.63
*** -1.20 (0.38) -1.96; -0.44 0.003 -0.17 (0.28) -0.74; 0.41 0.57
Width femoral neck (cm) ** -0.076 (0.083) -0.242; -0.089 0.36 0.025 (0.084) -0.14; 0.19 0.77
*** -0.031 (0.033) -0.097; 0.036 0.36 0.010 (0.034) -0.058; 0.078 0.77
Area femoral neck (cm2) ** 0.07 (0.51) -0.95; 1.09 0.89 0.26 (0.34) -0.42; 0.95 0.44
*** 0.03 (0.20) -0.38; 0.44 0.89 0.11 (0.14) -0.17; 0.38 0.44
* Adjusted for sex, age (by 10-year groups), body-mass index (continuous), height (continuous), creatinine clearance (continuous), demented hip-
fracture cases (dichotomous) and non-demented hip-fracture cases (dichotomous) adjusted the analysis.
β;parameter estimate, SE; standard error
** per unit of log-transformed aluminium
*** per SD of log-transformed aluminiumBMC Musculoskeletal Disorders 2006, 7:69 http://www.biomedcentral.com/1471-2474/7/69
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between the aluminium content in bone and femoral-
neck width or area (Table 2).
Discussion
Our cross-sectional study suggests no major association
between the aluminium content of bone and BMD, BMC
or bone size, overall or in subgroups such as demented or
fractured cases. We are not aware of any previous studies
investigating whether aluminium might exert negative
effects on bone density, mass or size in humans. There are,
however, scientists who have examined the effect of alu-
minium on bone cells in vitro, but the results are some-
what conflicting, indicating that aluminium could have
negative or positive effects on bone metabolism, or none
at all. In fact, in osteopenic rats with normal renal func-
tion aluminium is able to induce bone formation [37],
and comparable results have been observed in dogs [38-
40]. Actually, in the former study both high osteoblastic
activity and high osteoclastic activity were observed simul-
taneously, representing a high bone-turnover rate, which
is an independent risk factor of fractures in humans [41].
There are also, on the contrary, animal studies in which
aluminium has been proven to inhibit osteoblastic activ-
ity and have a negative effect on bone mineralisation
[42,43] Indirectly, aluminium also seems to have a nega-
tive effect on bone by interfering with parathyroid hor-
mone (PTH) release and maybe the synthesis of PTH,
possibly by elevating the serum calcium level, and it also
seems to alter the homeostasis between calcium and
phosphorus [23,44-46]. These paradoxical effects in
experimental and animal studies of the metal, i.e. both
trophic osseous actions and bone-toxic actions, are enig-
matic and await further explanation.
Despite the experimental indications, no human studies
have shown that aluminium could induce bone forma-
tion. On the contrary, use of aluminium cooking pots
increases the risk of hip fractures [47] Two small pilot
studies [31,48] have analysed the aluminium content in
bone in patients with a hip fracture. The former study dis-
played that hip fracture cases with Alzheimer's disease had
higher aluminium levels in bone than non-demented hip
fracture cases, a finding that was not confirmed in the lat-
ter survey. Our recent larger case-control study displayed
no significant increased risk of hip fracture with high bone
levels of aluminium as well as it was a exponential
increase in aluminium content in bone with age [49]
Since age is also an important covariant in our present
analysis with BMD and BMC as outcomes we have chosen
to also mention the positive association with aluminium
content in bone with age.
Some discrepancies also exist between previously reported
normal aluminium contents in bone [50-52] that are
probably due to differences in study design and chemical
processing such as contamination of aluminium or other
interfering metal ions, and probably the choice of analyt-
ical method used. Most variability of the reported normal
content of aluminium in bone is probably due to contam-
ination, which is a serious problem when dealing with
samples containing low concentrations of aluminium
because of the ubiquitous nature of the element. Thus the
lowest recorded values are probably the most correct ones
[53] This observation is supported by the results of one of
our previous studies using a meticulous analytical tech-
nique on a large group of humans. We observed that the
values for younger individuals and individuals in midlife
were close to the lowest values previously published in the
literature [49].
Selection bias is a potential limitation of our study. It can
be argued that the patients in the study group are not truly
representative of the population since they were admitted
to the hospital and included in the study because of injury
or osteoarthritis, and thus cannot be considered entirely
healthy. Chronic low-grade aluminium intoxication is,
however, not expected to play a role in the development
of osteoarthritis, and we also consider it unlikely that our
cases were accidentally selected as a result of the alumin-
ium status of the bone.
Our crude results indicated a strong negative association
between the aluminium content of bone and the amount
of bone in the proximal femur. These associations disap-
peared after multivariate adjustment, especially age
adjustment. The confidence intervals for the adjusted
results indicate that at least half of the crude association
was explained by confounding. Our sample size was suffi-
cient for detection of moderate effects. According to our
Tertiles Al-BMC Figure 2
Tertiles Al-BMC. Average adjusted bone-mineral density 
and content values of the femoral neck by tertiles of alumin-
ium content of bone. Included in the multivariate model were 
sex, age (by 10-year groups), body-mass index (continuous), 
height (continuous), creatinine clearance (continuous), 
demented hip fracture cases (dichotomous) and non-
demented hip-fracture cases (dichotomous).
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multivariate adjusted confidence intervals of the parame-
ter estimates, we had a 95% chance of detecting a 2–3%
difference in bone mineral density or mass of the proxi-
mal femur for each standard deviation change in bone
aluminium.
None of the patients were excluded from the analysis, nor
were any of our participants treated for renal failure. Even
though renal failure and dialysis are associated with
higher bone aluminium levels [54,55], a more subtle
deterioration in kidney function is not known to induce
aluminium accrual in bone. Since none of our partici-
pants suffered severe renal failure or had been treated with
haemodialysis we consider it unlikely that renal function
explains the higher aluminium values among the oldest
individuals in our study. The accuracy of the diagnosis of
dementia is a possible shortcoming, since it is based on
medical records. A geriatric specialist made the diagnosis,
therefore it can be assumed that the diagnosis is fairly reli-
able.
Conclusion
In this study we have not been able to show any signifi-
cant association between the aluminium content in bone
and the degree of BMD, BMC or bone size of the proximal
femur measured using DXA. Thus, our study does not sup-
port the hypothesis that aluminium is involved in the
pathogenesis of osteoporosis.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
All authors participated in the design of the study and
drafting the manuscript.
All authors has read and approved the final manuscript.
Acknowledgements
The study was sponsored by the Swedish Alzheimer Foundation and the 
Swedish Research Council. Sincere thanks are due to Lena Dalnert and 
Lotta Classon, group leaders on OR, for their untiring efforts. We also wish 
to thank Ass. Professor Ulf Lindh and PhD student Peter Frisk for technical 
assistance.
References
1. Christian JC, Yu PL, Slemenda CW, Johnston CC Jr: Heritability of
bone mass: a longitudinal study in aging male twins.  Am J Hum
Genet 1989, 44(3):429-433.
2. Gueguen R, Jouanny P, Guillemin F, Kuntz C, Pourel J, Siest G: Seg-
regation analysis and variance components analysis of bone
mineral density in healthy families.  J Bone Miner Res 1995,
10(12):2017-2022.
3. Harris M, Nguyen TV, Howard GM, Kelly PJ, Eisman JA: Genetic and
environmental correlations between bone formation and
bone mineral density: a twin study.  Bone 1998, 22(2):141-145.
4. Pocock NA, Eisman JA, Hopper JL, Yeates MG, Sambrook PN, Eberl
S: Genetic determinants of bone mass in adults. A twin study.
J Clin Invest 1987, 80(3):706-710.
5. Slemenda CW, Christian JC, Williams CJ, Norton JA, Johnston CC Jr:
Genetic determinants of bone mass in adult women: a
reevaluation of the twin model and the potential importance
of gene interaction on heritability estimates.  J Bone Miner Res
1991, 6(6):561-567.
6. Cusack S, Cashman KD: Impact of genetic variation on meta-
bolic response of bone to diet.  Proc Nutr Soc 2003,
62(4):901-912.
7. Baldock PA, Eisman JA: Genetic determinants of bone mass.
Curr Opin Rheumatol 2004, 16(4):450-456.
8. Deng HW, Recker RR: Gene mapping and identification for
osteoporosis.  J Musculoskelet Neuronal Interact 2004, 4(1):91-100.
9. Recker RR: Genetic research in osteoporosis: Where are we?
Where should we go next?  J Musculoskelet Neuronal Interact 2004,
4(1):86-90.
10. Alfrey AC: Aluminum.  Adv Clin Chem 1983, 23:69-91.
11. Varo P, Koivistoinen P: Mineral element composition of Finish
foods.  Acta Agric Scand 1980, 22:161-171.
12. Drüeke TB: Intestinal absorption of aluminium in renal fail-
ure.  Nephrol Dial Transplant 2002, 17(Suppl 2):13-16.
13. Priest ND: Aluminium. Occurence and toxicity.  In Encyclopedia
of Human Nutrition Edited by: Sadler JJ, Caballero B. San Diego, CA,
USA: Academic Press; 1999:59-66. 
14. Yokel RA, McNamara PJ: Aluminium toxicokinetics: an updated
minireview.  Pharmacol Toxicol 2001, 88(4):159-167.
15. Pérez-Granados AM, Vaquero MP: Silicon, aluminium, arsenic
and lithium: essentiality and human health implications.  J
Nutr Health Aging 2002, 6(2):154-162.
16. Priest ND: The biological behaviour and bioavailability of alu-
minium in man, with special reference to studies employing
aluminium-26 as a tracer: review and study update.  J Environ
Monit 2004, 6(5):375-403.
17. Moore PB, Day JP, Taylor GA, Ferrier IN, Fifield LK, Edwardson JA:
Absorption of aluminium-26 in Alzheimer's disease, meas-
ured using accelerator mass spectrometry.  Dement Geriatr
Cogn Disord 2000, 11(2):66-69.
18. Taylor GA, Ferrier IN, McLoughlin IJ, Fairbairn AF, McKeith IG, Lett
D, Edwardson JA: Gastrointestinal absorption of aluminium in
Alzheimer's disease: response to aluminium citrate.  Age Age-
ing 1992, 21(2):81-90.
19. Alfrey AC: Aluminum metabolism and toxicity in uremia.  J
UOEH 1987, 9(Suppl):123-132.
20. Alfrey AC, LeGendre GR, Kaehny WD: The dialysis encephalop-
athy syndrome. Possible aluminum intoxication.  N Engl J Med
1976, 294(4):184-188.
21. Berlyne GM: Hyperaluminaemia from aluminium resins.  Lan-
cet 1970, 2(7685):1253.
22. Berlyne GM, Yagil R, Ari JB, Weinberger G, Knopf E, Danovitch GM:
Aluminium toxicity in rats.  Lancet 1972, 1(7750):564-568.
23. Cannata-Andia JB, Fernandez-Martin JL: The clinical impact of alu-
minium overload in renal failure.  Nephrol Dial Transplant 2002,
17(Suppl 2):9-12.
24. Hewitt CD, Savory J, Wills MR: Aspects of aluminum toxicity.
Clin Lab Med 1990, 10(2):403-422.
25. Nebeker HG, Coburn JW: Aluminum and renal osteodystro-
phy.  Annu Rev Med 1986, 37:79-95.
26. Parkinson IS, Ward MK, Feest TG, Fawcett RW, Kerr DN: Fractur-
ing dialysis osteodystrophy and dialysis encephalopathy. An
epidemiological survey.  Lancet 1979, 1(8113):406-409.
27. Sherrard DJ: Letter: The myth of aluminum toxicity.  N Engl J
Med 1974, 290(13):750.
28. Ward MK, Feest TG, Ellis HA, Parkinson IS, Kerr DN: Osteoma-
lacic dialysis osteodystrophy: Evidence for a water-borne
aetiological agent, probably aluminium.  Lancet 1978,
1(8069):841-845.
29. Ott SM: Aluminum accumulation in individuals with normal
renal function.  Am J Kidney Dis 1985, 6(5):297-301.
30. Mjoberg B: Aluminium-induced hip fractures: a hypothesis.  J
Bone Joint Surg Br 1989, 71(3):538.
31. Mjoberg B, Hellquist E, Mallmin H, Lindh U: Aluminum, Alzhe-
imer's disease and bone fragility.  Acta Orthop Scand 1997,
68(6):511-514.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Musculoskeletal Disorders 2006, 7:69 http://www.biomedcentral.com/1471-2474/7/69
Page 6 of 6
(page number not for citation purposes)
32. Klein GL: Aluminum in parenteral solutions revisited–again.
Am J Clin Nutr 1995, 61(3):449-456.
33. Ott SM, Maloney NA, Klein GL, Alfrey AC, Ament ME, Coburn JW,
Sherrard DJ: Aluminum is associated with low bone formation
in patients receiving chronic parenteral nutrition.  Ann Intern
Med 1983, 98(6):910-914.
34. Vargas JH, Klein GL, Ament ME, Ott SM, Sherrard DJ, Horst RL, Ber-
quist WE, Alfrey AC, Slatopolsky E, Coburn JW: Metabolic bone
disease of total parenteral nutrition: course after changing
from casein to amino acids in parenteral solutions with
reduced aluminum content.  Am J Clin Nutr 1988,
48(4):1070-1078.
35. Cockcroft DW, Gault MH: Prediction of creatinine clearance
from serum creatinine.  Nephron 1976, 16(1):31-41.
36. Hellstrom HO, Lindh U, Mjoberg B: Measurement accuracy of
aluminium content in bone.  Ups J Med Sci 2000, 105(1):67-71.
37. Gomez-Alonso C, Menendez-Rodriguez P, Virgos-Soriano MJ, Fern-
andez-Martin JL, Fernandez-Coto MT, Cannata-Andia JB: Alumi-
num-induced osteogenesis in osteopenic rats with normal
renal function.  Calcif Tissue Int 1999, 64(6):534-541.
38. Quarles LD: Paradoxical toxic and trophic osseous actions of
aluminum: potential explanations.  Miner Electrolyte Metab 1991,
17(4):233-239.
39. Quarles LD, Gitelman HJ, Drezner MK: Aluminum-induced de
novo bone formation in the beagle. A parathyroid hormone-
dependent event.  J Clin Invest 1989, 83(5):1644-1650.
40. Quarles LD, Murphy G, Vogler JB, Drezner MK: Aluminum-
induced neo-osteogenesis: a generalized process affecting
trabecular networking in the axial skeleton.  J Bone Miner Res
1990, 5(6):625-635.
41. Delmas PD, Recker RR, Chesnut CH 3, Skag A, Stakkestad JA, Emkey
R, Gilbride J, Schimmer RC, Christiansen C: Daily and intermit-
tent oral ibandronate normalize bone turnover and provide
significant reduction in vertebral fracture risk: results from
the BONE study.  Osteoporos Int 2004, 15(10):792-798.
42. Rodriguez M, Felsenfeld AJ, Llach F: Aluminum administration in
the rat separately affects the osteoblast and bone minerali-
zation.  J Bone Miner Res 1990, 5(1):59-67.
43. Zhu JM, Huffer W, Alfrey AC: Effect of aluminum on bone
matrix inductive properties.  Kidney Int 1990, 38(6):1141-1145.
44. Diaz-Corte C, Fernandez-Martin JL, Barreto S, Gomez C, Fernandez-
Coto T, Braga S, Cannata JB: Effect of aluminium load on parath-
yroid hormone synthesis.  Nephrol Dial Transplant 2001,
16(4):742-745.
45. Felsenfeld AJ, Machado L, Bover J, Trinidad P, Rodriguez M: Effect of
aluminium on the development of hyperparathyroidism and
bone disease in the azotaemic rat.  Nephrol Dial Transplant 1993,
8(4):325-334.
46. Mahieu ST, Navoni J, Millen N, Del Carmen Contini M, Gonzalez M,
Elias MM: Effects of aluminum on phosphate metabolism in
rats: a possible interaction with vitamin D(3) renal produc-
tion.  Arch Toxicol 2004 in press.
47. Cumming RG, Klineberg RJ: Aluminium in antacids and cooking
pots and the risk of hip fractures in elderly people.  Age Ageing
1994, 23(6):468-472.
48. O'Mahony D, Denton J, Templar J, O'Hara M, Day JP, Murphy S,
Walsh JB, Coakley D: Bone aluminium content in Alzheimer's
disease.  Dementia 1995, 6(2):69-72.
49. Hellstrom HO, Mjoberg B, Mallmin H, Michaelsson K: The alumi-
num content of bone increases with age, but is not higher in
hip fracture cases with and without dementia compared to
controls.  Osteoporos Int 2005 in press.
50. Bush VJ, Moyer TP, Batts KP, Parisi JE: Essential and toxic element
concentrations in fresh and formalin-fixed human autopsy
tissues.  Clin Chem 1995, 41(2):284-294.
51. Tahán JE, Granadillo VA, Romero RA: Electrothermal atomic
absorption spectrometric determination of Al, Cu, Fe, Pb, V
and Zn in clinical samples and in certified environmental ref-
erence materials.  Anal Chim Acta 1994, 295:187-197.
52. Tang S, Parsons PJ, Perl D: Longitudinal and lateral variations in
the aluminum concentration of selected caprine, bovine, and
human bone samples.  Biol Trace Elem Res 1999, 68(3):267-279.
53. Ganrot PO: Metabolism and possible health effects of alumi-
num.  Environ Health Perspect 1986, 65:363-441.
54. D'Haese PC, Couttenye MM, Lamberts LV, Elseviers MM, Goodman
WG, Schrooten I, Cabrera WE, De Broe ME: Aluminum, iron,
lead, cadmium, copper, zinc, chromium, magnesium, stron-
tium, and calcium content in bone of end-stage renal failure
patients.  Clin Chem 1999, 45(9):1548-1556.
55. Navarro JA, Granadillo VA, Salgado O, Rodriguez-Iturbe B, Garcia R,
Delling G, Romero RA: Bone metal content in patients with
chronic renal failure.  Clin Chim Acta 1992, 211(3):133-142.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2474/7/69/prepub